Table 4.
Predictive clinical factors of PFS after crizotinib treatment
| Clinical factors | Univariate analysis P value | Multivariate analysis | ||
|---|---|---|---|---|
| HR | 95%CI | P value | ||
| Gender (male versus female) | 0.318 | – | – | – |
| Age | 0.175 | – | – | – |
| Smoking history (smoker versus never smoker) | 0.255 | – | – | – |
| ECOG score (> = 2 versus 0 or 1) | 0.011 | 2.345 | 1.137–4.834 | 0.021 |
| TNM stage (IV versus IIIB) | 0.600 | – | – | – |
| BM status (with versus without BM before crzotinib) | 0.137 | – | – | – |
| First line treatment (N1-PP versus 1-PP or crizotinib) | 0.009 | 2.335 | 1.162–4.691 | 0.017 |
Note. —Covariates with a P ≤ 0.10 in univariate analysis were included in the multivariate model. Multivariate analysis was performed by using the Cox proportional hazards model